Search

Your search keyword '"Roqué Lloveras A"' showing total 12 results
Start Over Author "Roqué Lloveras A" Publication Year Range Last 10 years
12 results on '"Roqué Lloveras A"'

1. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Evans, Joanne S, Swallow, Judith, Chung, Chris, Patel, Meera, Dettorre, Gino, Ottaviani, Diego, Chowdhury, Amani, Merry, Eve, Chopra, Neha, Lee, Alvin JX, Sng, Christopher CT, Yu, Tamara, Shawe-Taylor, Marianne, Bain, Hamish DC, Wong, Yien Ning Sophia, Galazi, Myria, Benafif, Sarah, Dileo, Palma, Earnshaw, Irina, Patel, Grisma, Wu, Anjui, Soosaipillai, Gehan, Cooper, Lee, Andaleeb, Ramis, Dolly, Saoirse, Apthorp, Eleanor, Srikandarajah, Krishnie, Jones, Eleanor, Van Hemelrijck, Mieke, Moss, Charlotte, Russell, Beth, Chester, John, Loizidou, Angela, Piccart, Martine, Cruz, Claudia A, Reyes, Roxana, Segui, Elia, Marco-Hernández, Javier, Viladot, Margarita, Eremiev, Simeon, Fort-Culillas, Roser, Garcia, Isabel, Liñan, Raquel, Roqué Lloveras, Ariadna, Harbeck, Nadia, Wuerstlein, Rachel, Henze, Franziska, Mahner, Sven, Felip, Eudald, Pous, Anna, D'Avanzo, Francesca, Scotti, Lorenza, Krengli, Marco, Marrari, Andrea, Delfanti, Sara, Maconi, Antonio, Betti, Marta, Tonini, Giuseppe, Di Fazio, Giuseppina Rita, Tondini, Carlo, Chiudinelli, Lorenzo, Franchi, Michela, Libertini, Michela, Bertulli, Rossella, Baggi, Alice, Tovazzi, Valeria, Ficorella, Corrado, Porzio, Giampiero, Saponara, Maristella, Filetti, Marco, Zoratto, Federica, Paoloni, Francesco, Berardi, Rossana, Guida, Annalisa, Bracarda, Sergio, Iglesias, Maria, Sanchez de Torre, Ana, Tagliamento, Marco, Colomba, Emeline, Pommeret, Fanny, Pinato, David J, Aguilar-Company, Juan, Ferrante, Daniela, Hanbury, Georgina, Bower, Mark, Salazar, Ramon, Mirallas, Oriol, Sureda, Anna, Plaja, Andrea, Cucurull, Marc, Mesia, Ricard, Townsend, Sarah, Jackson, Amanda, Dalla Pria, Alessia, Newsom-Davis, Thomas, Handford, Jasmine, Sita-Lumsden, Ailsa, Vincenzi, Bruno, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Maluquer, Clara, Pedrazzoli, Paolo, Biello, Federica, Sinclair, Alasdair, Bawany, Samira, Khalique, Saira, Rossi, Sabrina, Rogers, Lucy, Murphy, Cian, Belessiotis, Katherine, Carmona-García, M Carmen, Sharkey, Rachel, García-Illescas, David, Rizzo, Gianpiero, Perachino, Marta, Saoudi-Gonzalez, Nadia, Doonga, Kris, Fox, Laura, Roldán, Elisa, Gaidano, Gianluca, Ruiz-Camps, Isabel, Bruna, Riccardo, Patriarca, Andrea, Martinez-Vila, Clara, Cantini, Luca, Zambelli, Alberto, Giusti, Raffaele, Mazzoni, Francesca, Caliman, Enrico, Santoro, Armando, Grosso, Federica, Parisi, Alessandro, Queirolo, Paola, Aujayeb, Avinash, Rimassa, Lorenza, Prat, Aleix, Tucci, Marco, Grisanti, Salvatore, Mukherjee, Uma, Diamantis, Nikolaos, Fusco, Vittorio, Generali, Daniele, Provenzano, Salvatore, Gennari, Alessandra, Tabernero, Josep, and Cortellini, Alessio

Published
2022
Full Text
View/download PDF

2. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Author

Swallow, Judith, Chung, Chris, Dettorre, Gino, Chopra, Neha, Lee, Alvin JX, Sng, Christopher CT, Wong, Yien Ning Sophia, Galazi, Myria, Benafif, Sarah, Dileo, Palma, Patel, Grisma, Wu, Anjui, Sinclair, Alasdair, Soosaipillai, Gehan, Jones, Eleanor, Diamantis, Nikolaos, Mukherjee, Uma, Jackson, Amanda, Piccart, Martine, Pommeret, Fanny, Colomba, Johann, Colomba-Blameble, Emeline, Prat, Aleix, Cruz, Claudia A, Reyes, Roxana, Segui, Elia, Marco-Hernández, Javier, Tabernero, Josep, Aguilar-Company, Juan, Ruiz-Camps, Isabel, Fox, Laura, Garcia Illescas, David, Mirallas, Oriol, Roldán, Elisa, Carbó, Anna, Garcia, Isabel, Wuerstlein, Rachel, Mesia, Ricard, Maluquer, Clara, D'Avanzo, Francesca, Tonini, Giuseppe, Provenzano, Salvatore, Tovazzi, Valeria, Ficorella, Corrado, Queirolo, Paola, Giusti, Raffaele, Mazzoni, Francesca, Zoratto, Federica, Tucci, Marco, Berardi, Rossana, Guida, Annalisa, Bracarda, Sergio, Iglesias, Maria, Pinato, David J, Bower, Mark, Scotti, Lorenza, Patel, Meera, Colomba, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Zambelli, Alberto, Dalla Pria, Alessia, Ottaviani, Diego, Chowdhury, Amani, Merry, Eve, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Tagliamento, Marco, Pous, Anna, Sita-Lumsden, Ailsa, Srikandarajah, Krishnie, Seguí, Elia, Generali, Daniele, Grisanti, Salvatore, Pedrazzoli, Paolo, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S, Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Biello, Federica, Bertulli, Rossella, Liñan, Raquel, Rossi, Sabrina, Carmona-García, Maria Carmen, Tondini, Carlo, Baggi, Alice, Fotia, Vittoria, Parisi, Alessandro, Porzio, Giampero, Saponara, Maristella, Cruz, Claudia Andrea, García-Illescas, David, Felip, Eudald, Roqué Lloveras, Ariadna, Sharkey, Rachel, Earnshaw, Irina, Ferrante, Daniela, Gaidano, Gianluca, Patriarca, Andrea, Bruna, Riccardo, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Cantini, Luca, Filetti, Marco, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Van Hemelrijck, Mieke, Newsom-Davis, Thomas, Gennari, Alessandra, and Cortellini, Alessio

Published
2021
Full Text
View/download PDF

4. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Pinato, David J, primary, Aguilar-Company, Juan, additional, Ferrante, Daniela, additional, Hanbury, Georgina, additional, Bower, Mark, additional, Salazar, Ramon, additional, Mirallas, Oriol, additional, Sureda, Anna, additional, Plaja, Andrea, additional, Cucurull, Marc, additional, Mesia, Ricard, additional, Townsend, Sarah, additional, Jackson, Amanda, additional, Dalla Pria, Alessia, additional, Newsom-Davis, Thomas, additional, Handford, Jasmine, additional, Sita-Lumsden, Ailsa, additional, Apthorp, Eleanor, additional, Vincenzi, Bruno, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Lambertini, Matteo, additional, Maluquer, Clara, additional, Pedrazzoli, Paolo, additional, Biello, Federica, additional, Sinclair, Alasdair, additional, Bawany, Samira, additional, Khalique, Saira, additional, Rossi, Sabrina, additional, Rogers, Lucy, additional, Murphy, Cian, additional, Belessiotis, Katherine, additional, Carmona-García, M Carmen, additional, Sharkey, Rachel, additional, García-Illescas, David, additional, Rizzo, Gianpiero, additional, Perachino, Marta, additional, Saoudi-Gonzalez, Nadia, additional, Doonga, Kris, additional, Fox, Laura, additional, Roldán, Elisa, additional, Gaidano, Gianluca, additional, Ruiz-Camps, Isabel, additional, Bruna, Riccardo, additional, Patriarca, Andrea, additional, Martinez-Vila, Clara, additional, Cantini, Luca, additional, Zambelli, Alberto, additional, Giusti, Raffaele, additional, Mazzoni, Francesca, additional, Caliman, Enrico, additional, Santoro, Armando, additional, Grosso, Federica, additional, Parisi, Alessandro, additional, Queirolo, Paola, additional, Aujayeb, Avinash, additional, Rimassa, Lorenza, additional, Prat, Aleix, additional, Tucci, Marco, additional, Libertini, Michela, additional, Grisanti, Salvatore, additional, Mukherjee, Uma, additional, Diamantis, Nikolaos, additional, Fusco, Vittorio, additional, Generali, Daniele, additional, Provenzano, Salvatore, additional, Gennari, Alessandra, additional, Tabernero, Josep, additional, Cortellini, Alessio, additional, Evans, Joanne S, additional, Swallow, Judith, additional, Chung, Chris, additional, Patel, Meera, additional, Dettorre, Gino, additional, Ottaviani, Diego, additional, Chowdhury, Amani, additional, Merry, Eve, additional, Chopra, Neha, additional, Lee, Alvin JX, additional, Sng, Christopher CT, additional, Yu, Tamara, additional, Shawe-Taylor, Marianne, additional, Bain, Hamish DC, additional, Wong, Yien Ning Sophia, additional, Galazi, Myria, additional, Benafif, Sarah, additional, Dileo, Palma, additional, Earnshaw, Irina, additional, Patel, Grisma, additional, Wu, Anjui, additional, Soosaipillai, Gehan, additional, Cooper, Lee, additional, Andaleeb, Ramis, additional, Dolly, Saoirse, additional, Srikandarajah, Krishnie, additional, Jones, Eleanor, additional, Van Hemelrijck, Mieke, additional, Moss, Charlotte, additional, Russell, Beth, additional, Chester, John, additional, Loizidou, Angela, additional, Piccart, Martine, additional, Cruz, Claudia A, additional, Reyes, Roxana, additional, Segui, Elia, additional, Marco-Hernández, Javier, additional, Viladot, Margarita, additional, Eremiev, Simeon, additional, Fort-Culillas, Roser, additional, Garcia, Isabel, additional, Liñan, Raquel, additional, Roqué Lloveras, Ariadna, additional, Harbeck, Nadia, additional, Wuerstlein, Rachel, additional, Henze, Franziska, additional, Mahner, Sven, additional, Felip, Eudald, additional, Pous, Anna, additional, D'Avanzo, Francesca, additional, Scotti, Lorenza, additional, Krengli, Marco, additional, Marrari, Andrea, additional, Delfanti, Sara, additional, Maconi, Antonio, additional, Betti, Marta, additional, Tonini, Giuseppe, additional, Di Fazio, Giuseppina Rita, additional, Tondini, Carlo, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Bertulli, Rossella, additional, Baggi, Alice, additional, Tovazzi, Valeria, additional, Ficorella, Corrado, additional, Porzio, Giampiero, additional, Saponara, Maristella, additional, Filetti, Marco, additional, Zoratto, Federica, additional, Paoloni, Francesco, additional, Berardi, Rossana, additional, Guida, Annalisa, additional, Bracarda, Sergio, additional, Iglesias, Maria, additional, Sanchez de Torre, Ana, additional, Tagliamento, Marco, additional, Colomba, Emeline, additional, and Pommeret, Fanny, additional

Published
2022
Full Text
View/download PDF

5. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

David J Pinato, Juan Aguilar-Company, Daniela Ferrante, Georgina Hanbury, Mark Bower, Ramon Salazar, Oriol Mirallas, Anna Sureda, Andrea Plaja, Marc Cucurull, Ricard Mesia, Sarah Townsend, Amanda Jackson, Alessia Dalla Pria, Thomas Newsom-Davis, Jasmine Handford, Ailsa Sita-Lumsden, Eleanor Apthorp, Bruno Vincenzi, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Clara Maluquer, Paolo Pedrazzoli, Federica Biello, Alasdair Sinclair, Samira Bawany, Saira Khalique, Sabrina Rossi, Lucy Rogers, Cian Murphy, Katherine Belessiotis, M Carmen Carmona-García, Rachel Sharkey, David García-Illescas, Gianpiero Rizzo, Marta Perachino, Nadia Saoudi-Gonzalez, Kris Doonga, Laura Fox, Elisa Roldán, Gianluca Gaidano, Isabel Ruiz-Camps, Riccardo Bruna, Andrea Patriarca, Clara Martinez-Vila, Luca Cantini, Alberto Zambelli, Raffaele Giusti, Francesca Mazzoni, Enrico Caliman, Armando Santoro, Federica Grosso, Alessandro Parisi, Paola Queirolo, Avinash Aujayeb, Lorenza Rimassa, Aleix Prat, Marco Tucci, Michela Libertini, Salvatore Grisanti, Uma Mukherjee, Nikolaos Diamantis, Vittorio Fusco, Daniele Generali, Salvatore Provenzano, Alessandra Gennari, Josep Tabernero, Alessio Cortellini, Joanne S Evans, Judith Swallow, Chris Chung, Meera Patel, Gino Dettorre, Diego Ottaviani, Amani Chowdhury, Eve Merry, Neha Chopra, Alvin JX Lee, Christopher CT Sng, Tamara Yu, Marianne Shawe-Taylor, Hamish DC Bain, Yien Ning Sophia Wong, Myria Galazi, Sarah Benafif, Palma Dileo, Irina Earnshaw, Grisma Patel, Anjui Wu, Gehan Soosaipillai, Lee Cooper, Ramis Andaleeb, Saoirse Dolly, Krishnie Srikandarajah, Eleanor Jones, Mieke Van Hemelrijck, Charlotte Moss, Beth Russell, John Chester, Angela Loizidou, Martine Piccart, Claudia A Cruz, Roxana Reyes, Elia Segui, Javier Marco-Hernández, Margarita Viladot, Simeon Eremiev, Roser Fort-Culillas, Isabel Garcia, Raquel Liñan, Ariadna Roqué Lloveras, Nadia Harbeck, Rachel Wuerstlein, Franziska Henze, Sven Mahner, Eudald Felip, Anna Pous, Francesca D'Avanzo, Lorenza Scotti, Marco Krengli, Andrea Marrari, Sara Delfanti, Antonio Maconi, Marta Betti, Giuseppe Tonini, Giuseppina Rita Di Fazio, Carlo Tondini, Lorenzo Chiudinelli, Michela Franchi, Rossella Bertulli, Alice Baggi, Valeria Tovazzi, Corrado Ficorella, Giampiero Porzio, Maristella Saponara, Marco Filetti, Federica Zoratto, Francesco Paoloni, Rossana Berardi, Annalisa Guida, Sergio Bracarda, Maria Iglesias, Ana Sanchez de Torre, Marco Tagliamento, Emeline Colomba, and Fanny Pommeret

Subjects
Male, SARS-CoV-2, COVID-19, Middle Aged, Disease Outbreaks, Europe, Oxygen, COVID-19 Testing, Oncology, Neoplasms, Humans, Female, Registries, Aged, Retrospective Studies
Abstract

The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe.In this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing.As of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47·4%] were women and 1822 [52·6%] were men, with a median age of 68 years [IQR 57-77]). 2033 (58·5%) of 3473 were diagnosed during the prevaccination phase, 1075 (31·0%) during the alpha-delta phase, and 365 (10·5%) during the omicron phase. Among patients diagnosed during the omicron phase, 113 (33·3%) of 339 were fully vaccinated and 165 (48·7%) were boosted, whereas among those diagnosed during the alpha-delta phase, 152 (16·6%) of 915 were fully vaccinated and 21 (2·3%) were boosted. Compared with patients diagnosed during the prevaccination period, those who were diagnosed during the omicron phase had lower case-fatality rates at 14 days (adjusted odds ratio [OR] 0·32 [95% CI 0·19-0·61) and 28 days (0·34 [0·16-0·79]), complications due to COVID-19 (0·26 [0·17-0·46]), and hospitalisation due to COVID-19 (0·17 [0·09-0·32]), and had less requirements for COVID-19-specific therapy (0·22 [0·15-0·34]) and oxygen therapy (0·24 [0·14-0·43]) than did those diagnosed during the alpha-delta phase. Unvaccinated patients diagnosed during the omicron phase had similar crude case-fatality rates at 14 days (ten [25%] of 40 patients vs 114 [17%] of 656) and at 28 days (11 [27%] of 40 vs 184 [28%] of 656) and similar rates of hospitalisation due to COVID-19 (18 [43%] of 42 vs 266 [41%] of 652) and complications from COVID-19 (13 [31%] of 42 vs 237 [36%] of 659) as those diagnosed during the alpha-delta phase.Despite time-dependent improvements in outcomes reported in the omicron phase compared with the earlier phases of the pandemic, patients with cancer remain highly susceptible to SARS-CoV-2 if they are not vaccinated against SARS-CoV-2. Our findings support universal vaccination of patients with cancer as a protective measure against morbidity and mortality from COVID-19.National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust.

Published
2022

6. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry

Author

Gianpiero Rizzo, Eudald Felip, Annalisa Guida, Alessio Cortellini, Francesca Mazzoni, Rachel Sharkey, Alice Baggi, Emeline Colomba, Sabrina Rossi, Salvatore Grisanti, Federica Zoratto, David J. Pinato, Daniela Ferrante, Claudia Andrea Cruz, Giampero Porzio, Lorenzo Chiudinelli, Alessandra Gennari, Alexia Bertuzzi, Gianluca Gaidano, Joan Brunet, Johann Colomba, Alessia Dalla Pria, Nadia Harbeck, Raffaele Giusti, Alberto Zambelli, Angela Loizidou, Clara Martinez-Vila, Daniele Generali, Matteo Lambertini, Isabel Ruiz-Camps, Paola Queirolo, Michela Libertini, Ana Sanchez de Torre, Ailsa Sita-Lumsden, Laura Fox, Federica Biello, Javier Marco-Hernández, Nikolaos Diamantis, Elia Seguí, Lorenza Rimassa, Nadia Saoudi-Gonzalez, Ariadna Roqué Lloveras, Armando Santoro, John D. Chester, Mieke Van Hemelrijck, Carlo Tondini, Marco Krengli, Saoirse Dolly, Raquel Liñan, Elisa Roldán, Charlotte Moss, Diego Ottaviani, Fanny Pommeret, Uma Mukherjee, Andrea Patriarca, Aleix Prat, Joanne Evans, Rossana Berardi, Meera Patel, Mark Bower, Marco Tagliamento, Paolo Pedrazzoli, Juan Aguilar-Company, Lorenza Scotti, Bruno Vincenzi, Irina Earnshaw, M Carmen Carmona-García, Anna Pous, Thomas Newsom-Davis, Riccardo Bruna, Krishnie Srikandarajah, Rossella Bertulli, Josep Tabernero, Vittoria Fotia, Alessandro Parisi, Anna Sureda, Ramon Salazar, Beth Russell, Michela Franchi, Roxana Reyes, Pinato, D. J., Patel, M., Scotti, L., Colomba, E., Dolly, S., Loizidou, A., Chester, J., Mukherjee, U., Zambelli, A., Dalla Pria, A., Aguilar-Company, J., Bower, M., Salazar, R., Bertuzzi, A., Brunet, J., Lambertini, M., Tagliamento, M., Pous, A., Sita-Lumsden, A., Srikandarajah, K., Colomba, J., Pommeret, F., Segui, E., Generali, D., Grisanti, S., Pedrazzoli, P., Rizzo, G., Libertini, M., Moss, C., Evans, J. S., Russell, B., Harbeck, N., Vincenzi, B., Biello, F., Bertulli, R., Ottaviani, D., Linan, R., Rossi, S., Carmona-Garcia, M. C., Tondini, C., Fox, L., Baggi, A., Fotia, V., Parisi, A., Porzio, G., Queirolo, P., Cruz, C. A., Saoudi-Gonzalez, N., Felip, E., Roque Lloveras, A., Newsom-Davis, T., Sharkey, R., Roldan, E., Reyes, R., Zoratto, F., Earnshaw, I., Ferrante, D., Marco-Hernandez, J., Ruiz-Camps, I., Gaidano, G., Patriarca, A., Bruna, R., Sureda, A., Martinez-Vila, C., Sanchez De Torre, A., Berardi, R., Giusti, R., Mazzoni, F., Guida, A., Rimassa, L., Chiudinelli, L., Franchi, M., Krengli, M., Santoro, A., Prat, A., Tabernero, J., Van Hemelrijck, M., Diamantis, N., Gennari, A., and Cortellini, A.

Subjects
Male, Cancer Research, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), solid cancer, Internal medicine, Neoplasms, Tumor stage, COVID-19, real-world data, hematologic cancer, medicine, Humans, In patient, Registries, Pandemics, Aged, Original Investigation, business.industry, SARS-CoV-2, Hazard ratio, Outbreak, Cancer, Infant, medicine.disease, Female, Oncology, business, Case series
Abstract

IMPORTANCE Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. OBJECTIVE To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic. DESIGN, SETTING, AND PARTICIPANTS OnCovid is a European registry that collects data on consecutive patients with solid or hematologic cancer and COVID-19. This multicenter case series study included real-world data from 35 institutions across 6 countries (UK, Italy, Spain, France, Belgium, and Germany). This update included patients diagnosed between February 27, 2020, and February, 14, 2021. Inclusion criteria were confirmed diagnosis of SARS-CoV-2 infection and a history of solid or hematologic cancer. EXPOSURES SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES Deaths were differentiated at 14 days and 3 months as the 2 landmark end points. Patient characteristics and outcomes were compared by stratifying patients across 5 phases (February to March 2020, April to June 2020, July to September 2020, October to December 2020, and January to February 2021) and across 2 major outbreaks (February to June 2020 and July 2020 to February 2021). RESULTS At data cutoff, 2795 consecutive patients were included, with 2634 patients eligible for analysis (median [IQR] age, 68 [18-77] years ; 52.8% men). Eligible patients demonstrated significant time-dependent improvement in 14-day case-fatality rate (CFR) with estimates of 29.8% (95% CI, 0.26-0.33) for February to March 2020; 20.3% (95% CI, 0.17-0.23) for April to June 2020;12.5% (95% Cl, 0.06-22.90) for July to September 2020; 17.2% (95% CI, 0.15-0.21) for October to December 2020; and 14.5% (95% CI, 0.09-0.21) for January to February 2021(all P < .001) across the predefined phases. Compared with the second major outbreak, patients diagnosed in the first outbreak were more likely to be 65 years or older (974 of 1626 [60.3%] vs 564 of 1008 [56.1%]; P = .03), have at least 2 comorbidities (793 of 1626 [48.8%) vs 427 of 1008 [42.4%); P = .001), and have advanced tumors (708 of 1626 [46.4%) vs 536 of 1008 [56.1%]: P < .001). Complications of COVID-19 were more likely to be seen (738 of 1626 [45.4%) vs 342 of 1008 [33.9%]; P < .001) and require hospitalization (969 of 1626 [59.8%) vs 418 of 1008 [42.1%); P < .001) and anti-COVID-19 therapy (1004 of 1626 [61.7%) vs 501of 1008 [49.7%); P < .001) during the first major outbreak. The 14-day CFRs for the first and second major outbreaks were 25.6% (95% CI, 0.23-0.28) vs 16.2% (95% CI, 0.13-0.19; P < .001), respectively. After adjusting for country, sex, age, comorbidities, tumor stage and status, anti-COVID-19 and anticancer therapy, and COVID-19 complications, patients diagnosed in the first outbreak had an increased risk of death at 14 days (hazard ratio [HR], 1.85; 95% CI, 1.47-2.32) and 3 months (HR, 1.28; 95% CI, 1.08-1.51) compared with those diagnosed in the second outbreak. CONCLUSIONS AND RELEVANCE The findings of this registry-based study suggest that mortality in patients with cancer diagnosed with COVID-19 has improved in Europe; this improvement may be associated with earlier diagnosis, improved management, and dynamic changes in community transmission over time.

Published
2021

7. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Author

David J Pinato, Josep Tabernero, Mark Bower, Lorenza Scotti, Meera Patel, Emeline Colomba, Saoirse Dolly, Angela Loizidou, John Chester, Uma Mukherjee, Alberto Zambelli, Alessia Dalla Pria, Juan Aguilar-Company, Diego Ottaviani, Amani Chowdhury, Eve Merry, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Marco Tagliamento, Anna Pous, Ailsa Sita-Lumsden, Krishnie Srikandarajah, Johann Colomba, Fanny Pommeret, Elia Seguí, Daniele Generali, Salvatore Grisanti, Paolo Pedrazzoli, Gianpiero Rizzo, Michela Libertini, Charlotte Moss, Joanne S Evans, Beth Russell, Nadia Harbeck, Bruno Vincenzi, Federica Biello, Rossella Bertulli, Raquel Liñan, Sabrina Rossi, Maria Carmen Carmona-García, Carlo Tondini, Laura Fox, Alice Baggi, Vittoria Fotia, Alessandro Parisi, Giampero Porzio, Maristella Saponara, Claudia Andrea Cruz, David García-Illescas, Eudald Felip, Ariadna Roqué Lloveras, Rachel Sharkey, Elisa Roldán, Roxana Reyes, Irina Earnshaw, Daniela Ferrante, Javier Marco-Hernández, Isabel Ruiz-Camps, Gianluca Gaidano, Andrea Patriarca, Riccardo Bruna, Anna Sureda, Clara Martinez-Vila, Ana Sanchez de Torre, Luca Cantini, Marco Filetti, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Marco Krengli, Armando Santoro, Aleix Prat, Mieke Van Hemelrijck, Nikolaos Diamantis, Thomas Newsom-Davis, Alessandra Gennari, Alessio Cortellini, Judith Swallow, Chris Chung, Gino Dettorre, Neha Chopra, Alvin JX Lee, Christopher CT Sng, Yien Ning Sophia Wong, Myria Galazi, Sarah Benafif, Palma Dileo, Grisma Patel, Anjui Wu, Alasdair Sinclair, Gehan Soosaipillai, Eleanor Jones, Amanda Jackson, Martine Piccart, Emeline Colomba-Blameble, Claudia A Cruz, Elia Segui, David Garcia Illescas, Oriol Mirallas, Anna Carbó, Isabel Garcia, Rachel Wuerstlein, Ricard Mesia, Clara Maluquer, Francesca D'Avanzo, Giuseppe Tonini, Salvatore Provenzano, Valeria Tovazzi, Corrado Ficorella, Paola Queirolo, Raffaele Giusti, Francesca Mazzoni, Federica Zoratto, Marco Tucci, Rossana Berardi, Annalisa Guida, Sergio Bracarda, Maria Iglesias, Pinato, D. J., Tabernero, J., Bower, M., Scotti, L., Patel, M., Colomba, E., Dolly, S., Loizidou, A., Chester, J., Mukherjee, U., Zambelli, A., Dalla Pria, A., Aguilar-Company, J., Ottaviani, D., Chowdhury, A., Merry, E., Salazar, R., Bertuzzi, A., Brunet, J., Lambertini, M., Tagliamento, M., Pous, A., Sita-Lumsden, A., Srikandarajah, K., Colomba, J., Pommeret, F., Segui, E., Generali, D., Grisanti, S., Pedrazzoli, P., Rizzo, G., Libertini, M., Moss, C., Evans, J. S., Russell, B., Harbeck, N., Vincenzi, B., Biello, F., Bertulli, R., Linan, R., Rossi, S., Carmona-Garcia, M. C., Tondini, C., Fox, L., Baggi, A., Fotia, V., Parisi, A., Porzio, G., Saponara, M., Cruz, C. A., Garcia-Illescas, D., Felip, E., Roque Lloveras, A., Sharkey, R., Roldan, E., Reyes, R., Earnshaw, I., Ferrante, D., Marco-Hernandez, J., Ruiz-Camps, I., Gaidano, G., Patriarca, A., Bruna, R., Sureda, A., Martinez-Vila, C., Sanchez de Torre, A., Cantini, L., Filetti, M., Rimassa, L., Chiudinelli, L., Franchi, M., Krengli, M., Santoro, A., Prat, A., Van Hemelrijck, M., Diamantis, N., Newsom-Davis, T., Gennari, A., Cortellini, A., Swallow, J., Chung, C., Dettorre, G., Chopra, N., Lee, A. J., Sng, C. C., Wong, Y. N. S., Galazi, M., Benafif, S., Dileo, P., Patel, G., Wu, A., Sinclair, A., Soosaipillai, G., Jones, E., Jackson, A., Piccart, M., Colomba-Blameble, E., Garcia Illescas, D., Mirallas, O., Carbo, A., Garcia, I., Wuerstlein, R., Mesia, R., Maluquer, C., D'Avanzo, F., Tonini, G., Provenzano, S., Tovazzi, V., Ficorella, C., Queirolo, P., Giusti, R., Mazzoni, F., Zoratto, F., Tucci, M., Berardi, R., Guida, A., Bracarda, S., and Iglesias, M.

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Belgium, COVID-19, Disease Progression, Female, France, Germany, Hospitalization, Humans, Italy, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasms, Prevalence, Registries, Retrospective Studies, Spain, United Kingdom, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Registry study, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), OnCovid, cancer treatment, Post-Acute COVID-19 Syndrome, Internal medicine, medicine, 80 and over, In patient, business.industry, Cancer, Retrospective cohort study, Articles, medicine.disease, Oncology, Research centre, Population study, business
Abstract

Background: The medium-term and long-term impact of COVID-19 in patients with cancer is not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and their impact on the survival of patients with cancer. We also aimed to describe patterns of resumption and modifications of systemic anti-cancer therapy following recovery from SARS-CoV-2 infection. Methods: OnCovid is an active European registry study enrolling consecutive patients aged 18 years or older with a history of solid or haematological malignancy and who had a diagnosis of RT-PCR confirmed SARS-CoV-2 infection. For this retrospective study, patients were enrolled from 35 institutions across Belgium, France, Germany, Italy, Spain, and the UK. Patients who were diagnosed with SARS-CoV-2 infection between Feb 27, 2020, and Feb 14, 2021, and entered into the registry at the point of data lock (March 1, 2021), were eligible for analysis. The present analysis was focused on COVID-19 survivors who underwent clinical reassessment at each participating institution. We documented prevalence of COVID-19 sequelae and described factors associated with their development and their association with post-COVID-19 survival, which was defined as the interval from post-COVID-19 reassessment to the patients’ death or last follow-up. We also evaluated resumption of systemic anti-cancer therapy in patients treated within 4 weeks of COVID-19 diagnosis. The OnCovid study is registered in ClinicalTrials.gov, NCT04393974. Findings: 2795 patients diagnosed with SARS-CoV-2 infection between Feb 27, 2020, and Feb 14, 2021, were entered into the study by the time of the data lock on March 1, 2021. After the exclusion of ineligible patients, the final study population consisted of 2634 patients. 1557 COVID-19 survivors underwent a formal clinical reassessment after a median of 22·1 months (IQR 8·4–57·8) from cancer diagnosis and 44 days (28–329) from COVID-19 diagnosis. 234 (15·0%) patients reported COVID-19 sequelae, including respiratory symptoms (116 [49·6%]) and residual fatigue (96 [41·0%]). Sequelae were more common in men (vs women; p=0·041), patients aged 65 years or older (vs other age groups; p=0·048), patients with two or more comorbidities (vs one or none; p=0·0006), and patients with a history of smoking (vs no smoking history; p=0·0004). Sequelae were associated with hospitalisation for COVID-19 (p

Published
2021

8. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Author

Pinato, David J, primary, Tabernero, Josep, additional, Bower, Mark, additional, Scotti, Lorenza, additional, Patel, Meera, additional, Colomba, Emeline, additional, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Dalla Pria, Alessia, additional, Aguilar-Company, Juan, additional, Ottaviani, Diego, additional, Chowdhury, Amani, additional, Merry, Eve, additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Lambertini, Matteo, additional, Tagliamento, Marco, additional, Pous, Anna, additional, Sita-Lumsden, Ailsa, additional, Srikandarajah, Krishnie, additional, Colomba, Johann, additional, Pommeret, Fanny, additional, Seguí, Elia, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Pedrazzoli, Paolo, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Moss, Charlotte, additional, Evans, Joanne S, additional, Russell, Beth, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Biello, Federica, additional, Bertulli, Rossella, additional, Liñan, Raquel, additional, Rossi, Sabrina, additional, Carmona-García, Maria Carmen, additional, Tondini, Carlo, additional, Fox, Laura, additional, Baggi, Alice, additional, Fotia, Vittoria, additional, Parisi, Alessandro, additional, Porzio, Giampero, additional, Saponara, Maristella, additional, Cruz, Claudia Andrea, additional, García-Illescas, David, additional, Felip, Eudald, additional, Roqué Lloveras, Ariadna, additional, Sharkey, Rachel, additional, Roldán, Elisa, additional, Reyes, Roxana, additional, Earnshaw, Irina, additional, Ferrante, Daniela, additional, Marco-Hernández, Javier, additional, Ruiz-Camps, Isabel, additional, Gaidano, Gianluca, additional, Patriarca, Andrea, additional, Bruna, Riccardo, additional, Sureda, Anna, additional, Martinez-Vila, Clara, additional, Sanchez de Torre, Ana, additional, Cantini, Luca, additional, Filetti, Marco, additional, Rimassa, Lorenza, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Krengli, Marco, additional, Santoro, Armando, additional, Prat, Aleix, additional, Van Hemelrijck, Mieke, additional, Diamantis, Nikolaos, additional, Newsom-Davis, Thomas, additional, Gennari, Alessandra, additional, Cortellini, Alessio, additional, Swallow, Judith, additional, Chung, Chris, additional, Dettorre, Gino, additional, Chopra, Neha, additional, Lee, Alvin JX, additional, Sng, Christopher CT, additional, Wong, Yien Ning Sophia, additional, Galazi, Myria, additional, Benafif, Sarah, additional, Dileo, Palma, additional, Patel, Grisma, additional, Wu, Anjui, additional, Sinclair, Alasdair, additional, Soosaipillai, Gehan, additional, Jones, Eleanor, additional, Jackson, Amanda, additional, Piccart, Martine, additional, Colomba-Blameble, Emeline, additional, Cruz, Claudia A, additional, Segui, Elia, additional, Garcia Illescas, David, additional, Mirallas, Oriol, additional, Carbó, Anna, additional, Garcia, Isabel, additional, Wuerstlein, Rachel, additional, Mesia, Ricard, additional, Maluquer, Clara, additional, D'Avanzo, Francesca, additional, Tonini, Giuseppe, additional, Provenzano, Salvatore, additional, Tovazzi, Valeria, additional, Ficorella, Corrado, additional, Queirolo, Paola, additional, Giusti, Raffaele, additional, Mazzoni, Francesca, additional, Zoratto, Federica, additional, Tucci, Marco, additional, Berardi, Rossana, additional, Guida, Annalisa, additional, Bracarda, Sergio, additional, and Iglesias, Maria, additional

Published
2021
Full Text
View/download PDF

9. Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

Author

Pinato, David J., Scotti, Lorenza, Gennari, Alessandra, Colomba-Blameble, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Aguilar-Company, Juan, Bower, Mark, Galazi, Myria, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Wuerstlein, Rachel, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona-García, M. Carmen, Sng, Christopher CT., Tondini, Carlo, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi-Gonzalez, Nadia, Felip, Eudald, Roqué Lloveras, Ariadna, Lee, Alvin J.X., Newsom-Davis, Thomas, Sharkey, Rachel, Chung, Chris, García-Illescas, David, Reyes, Roxana, Sophia Wong, Yien Ning, Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, Van Hemelrijck, Mieke, Diamantis, Nikolaos, and Cortellini, Alessio

Subjects
Europe, SARS-CoV-2, COVID-19, cancer, UK, Mortality, Original Research
Abstract

Background Despite high contagiousness and rapid spread, SARS-CoV-2 has led to heterogeneous outcomes across affected nations. Within Europe, the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100.000 as of January 2021. We aimed to compare the national impact of COVID-19 on the risk of death in UK cancer patients versus those in continental Europe (EU). Methods We performed a retrospective analysis of the OnCovid study database, a European registry of cancer patients consecutively diagnosed with COVID-19 in 27 centres from February 27 to September 10, 2020. We analysed case fatality rates and risk of death at 30 days and 6 months stratified by region of origin (UK versus EU). We compared patient characteristics at baseline, including oncological and COVID-19 specific therapy across UK and EU cohorts and evaluated the association of these factors with the risk adverse outcome in multivariable Cox regression models. Findings Compared to EU (n=924), UK patients (n=468) were characterised by higher case fatality rates (40.38% versus 26.5%, p

Published
2021

10. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

Author

Elia Seguí, Nadia Saoudi-Gonzalez, Federica Biello, Rachel Wuerstlein, Andrea Marrari, Carlo Tondini, Ramon Salazar, Lorenza Rimassa, Claudia Andrea Cruz, Nikolaos Diamantis, David J. Pinato, Armando Santoro, Salvatore Grisanti, Clara Martinez-Vila, Charlotte Moss, Lorenzo Chiudinelli, Daniele Generali, M. C. Carmona-Garcia, Vittoria Fotia, Alexia Bertuzzi, Ailsa Sita-Lumsden, Angela Loizidou, Christopher C T Sng, Bruno Vincenzi, Alessandra Gennari, Aleix Prat, David García-Illescas, Chris Chung, Fanny Pommeret, Diego Ottaviani, Daniela Ferrante, Ariadna Roqué Lloveras, Joan Brunet, Johann Colomba, Joanne Evans, Uma Mukherjee, Alvin J.X. Lee, Juan Aguilar-Company, Andrea Patriarca, Myria Galazi, Gianluca Gaidano, Javier Marco-Hernández, Eudald Felip, Marco Krengli, Gianpiero Rizzo, Isabel Ruiz-Camps, Thomas Newsom-Davis, Mark Bower, John D. Chester, Saoirse Dolly, Yien N. Sophia Wong, Ricard Mesia, Michela Franchi, Michela Libertini, Alessio Cortellini, Roxana Reyes, Lorenza Scotti, Josep Tabernero, Rossella Bertulli, Oriol Mirallas, Valeria Tovazzi, Emeline Colomba-Blameble, Anna Sureda, Beth Russell, Raquel Liñan, Rachel Sharkey, Mieke Van Hemelrijck, Alberto Zambelli, Ana Sanchez de Torre, Pinato, David J., Scotti, Lorenza, Gennari, Alessandra, Colomba-Blameble, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Aguilar-Company, Juan, Bower, Mark, Galazi, Myria, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Wuerstlein, Rachel, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona-García, M. C., Sng, Christopher. C. T., Tondini, Carlo, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia A., Saoudi-Gonzalez, Nadia, Felip, Eudald, R. Lloveras, Ariadna, Lee, Alvin. J. X., Newsom-Davis, Thoma, Sharkey, Rachel, Chung, Chri, García-Illescas, David, Reyes, Roxana, Sophia Wong, Yien N., Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, V. Hemelrijck, Mieke, Diamantis, Nikolao, and Cortellini, Alessio

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Epidemiology, Case fatality rate, medicine, COVID-19, Cancer, Europe, Mortality, SARS-CoV-2, UK, Mechanical ventilation, business.industry, Proportional hazards model, medicine.disease, Comorbidity, Confidence interval, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cohort, business
Abstract

Background: Despite high contagiousness and rapid spread, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare the national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients with cancer versus those in continental EU. Methods: We performed a retrospective analysis of the OnCovid study database, a European registry of patients with cancer consecutively diagnosed with COVID-19 in 27 centres from 27th February to 10th September 2020. We analysed case fatality rates and risk of death at 30 days and 6 months stratified by region of origin (UK versus EU). We compared patient characteristics at baseline including oncological and COVID-19-specific therapy across UKand EU cohorts and evaluated the association of these factors with the risk of adverse out-comes in multivariable Cox regression models Findings: Compared with EU (n = 924), UK patients (n = 468) were characterised by higher case fatality rates (40.38% versus 26.5%, p < 0.0001) and higher risk of death at 30 days (haz-ard ratio [HR], 1.64 [95% confidence interval {CI}, 1.36-1.99]) and 6 months after COVID-19 diagnosis (47.64% versus 33.33%; p < 0.0001; HR, 1.59 [95% CI, 1.33-1.88]). UK patients were more often men, were of older age and have more comorbidities than EU counterparts (p < 0.01). Receipt of anticancer therapy was lower in UK than in EU patients (p < 0.001). Despite equal proportions of complicated COVID-19, rates of intensive care admission and use of mechanical ventilation, UK patients with cancer were less likely to receive anti-COVID-19 therapies including corticosteroids, antivirals and inter leukin-6 antagonists (p < 0.0001). Multivariable analyses adjusted for imbalanced prognostic factors confirmed the UK cohort to be characterised by worse risk of death at 30 days and 6 months, indepen-dent of the patient's age, gender, tumour stage and status; number of comorbidities; COVID-19 severity and receipt of anticancer and anti-COVID-19 therapy. Rates of permanent cessa-tion of anticancer therapy after COVID-19 were similar in the UK and EU cohorts. Interpretation: UK patients with cancer have been more severely impacted by the unfolding of the COVID-19 pandemic despite societal risk mitigation factors and rapid deferral of anti-cancer therapy. The increased frailty of UK patients with cancer highlights high-risk groups that should be prioritised for anti-SARS-CoV-2 vaccination. Continued evaluation of long-term outcomes is warranted. (C) 2021 Elsevier Ltd. All rights reserved.

Published
2021

11. Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry

Author

Pinato, David J., Josep, Tabernero, Mark, Bower, Lorenza, Scotti, Meera, Patel, Emeline, Colomba, Saoirse, Dolly, Angela, Loizidou, John, Chester, Uma, Mukherjee, Alberto, Zambelli, Alessia Dalla Pria, Juan, Aguilar-Company, Diego, Ottaviani, Amani, Chowdhury, Eve, Merry, Ramon, Salazar, Alexia, Bertuzzi, Joan, Brunet, Matteo, Lambertini, Marco, Tagliamento, Anna, Pous, Ailsa, Sita-Lumsden, Krishnie, Srikandarajah, Johann, Colomba, Fanny, Pommeret, Elia, Seguí, Daniele, Generali, Salvatore, Grisanti, Paolo, Pedrazzoli, Gianpiero, Rizzo, Michela, Libertini, Charlotte, Moss, Evans, Joanne S., Beth, Russell, Nadia, Harbeck, Bruno, Vincenzi, Federica, Biello, Rossella, Bertulli, Raquel, Liñan, Sabrina, Rossi, Carmen Carmona-García, M., Carlo, Tondini, Laura, Fox, Alice, Baggi, Vittoria, Fotia, Alessandro, Parisi, Giampero, Porzio, Maristella, Saponara, Claudia Andrea Cruz, David, García-Illescas, Eudald, Felip, Ariadna Roqué Lloveras, Rachel, Sharkey, Elisa, Roldán, Roxana, Reyes, Irina, Earnshaw, Ferrante, Daniela, Javier, Marco-Hernández, Isabel, Ruiz-Camps, Gianluca, Gaidano, Andrea, Patriarca, Riccardo, Bruna, Anna, Sureda, Clara, Martinez-Vila, Ana Sanchez de Torre, Luca, Cantini, Marco, Filetti, Lorenza, Rimassa, Lorenzo, Chiudinelli, Michela, Franchi, Krengli, Marco, Armando, Santoro, Aleix, Prat, Mieke Van Hemelrijck, Nikolaos, Diamantis, Thomas, Newsom-Davis, Alessandra, Gennari, and Alessio, Cortellini.

Subjects
ANTICANCER TREATMENTSLONG-TERMMORTALITY
Published
2021

12. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry

Author

Pinato, David J., Patel, Meera, Scotti, Lorenza, Colomba, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Dalla Pria, Alessia, Aguilar-Company, Juan, Bower, Mark, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Tagliamento, Marco, Pous, Anna, Sita-Lumsden, Ailsa, Srikandarajah, Krishnie, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Generali, Daniele, Grisanti, Salvatore, Pedrazzoli, Paolo, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Biello, Federica, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Rossi, Sabrina, Carmona-García, M. Carmen, Tondini, Carlo, Fox, Laura, Baggi, Alice, Fotia, Vittoria, Parisi, Alessandro, Porzio, Giampero, Queirolo, Paola, Cruz, Claudia Andrea, Saoudi-Gonzalez, Nadia, Felip, Eudald, Roqué Lloveras, Ariadna, Newsom-Davis, Thomas, Sharkey, Rachel, Roldán, Elisa, Reyes, Roxana, Zoratto, Federica, Earnshaw, Irina, Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Bruna, Riccardo, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Berardi, Rossana, Giusti, Raffaele, Mazzoni, Francesca, Guida, Annalisa, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, Van Hemelrijck, Mieke, Diamantis, Nikolaos, Gennari, Alessandra, and Cortellini, Alessio

Abstract

IMPORTANCE: Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. OBJECTIVE: To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic. DESIGN, SETTING, AND PARTICIPANTS: OnCovid is a European registry that collects data on consecutive patients with solid or hematologic cancer and COVID-19. This multicenter case series study included real-world data from 35 institutions across 6 countries (UK, Italy, Spain, France, Belgium, and Germany). This update included patients diagnosed between February 27, 2020, and February, 14, 2021. Inclusion criteria were confirmed diagnosis of SARS-CoV-2 infection and a history of solid or hematologic cancer. EXPOSURES: SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: Deaths were differentiated at 14 days and 3 months as the 2 landmark end points. Patient characteristics and outcomes were compared by stratifying patients across 5 phases (February to March 2020, April to June 2020, July to September 2020, October to December 2020, and January to February 2021) and across 2 major outbreaks (February to June 2020 and July 2020 to February 2021). RESULTS: At data cutoff, 2795 consecutive patients were included, with 2634 patients eligible for analysis (median [IQR] age, 68 [18-77] years ; 52.8% men). Eligible patients demonstrated significant time-dependent improvement in 14-day case-fatality rate (CFR) with estimates of 29.8% (95% CI, 0.26-0.33) for February to March 2020; 20.3% (95% CI, 0.17-0.23) for April to June 2020; 12.5% (95% CI, 0.06-22.90) for July to September 2020; 17.2% (95% CI, 0.15-0.21) for October to December 2020; and 14.5% (95% CI, 0.09-0.21) for January to February 2021 (all P &lt; .001) across the predefined phases. Compared with the second major outbreak, patients diagnosed in the first outbreak were more likely to be 65 years or older (974 of 1626 [60.3%] vs 564 of 1008 [56.1%]; P = .03), have at least 2 comorbidities (793 of 1626 [48.8%] vs 427 of 1008 [42.4%]; P = .001), and have advanced tumors (708 of 1626 [46.4%] vs 536 of 1008 [56.1%]; P &lt; .001). Complications of COVID-19 were more likely to be seen (738 of 1626 [45.4%] vs 342 of 1008 [33.9%]; P &lt; .001) and require hospitalization (969 of 1626 [59.8%] vs 418 of 1008 [42.1%]; P &lt; .001) and anti–COVID-19 therapy (1004 of 1626 [61.7%] vs 501 of 1008 [49.7%]; P &lt; .001) during the first major outbreak. The 14-day CFRs for the first and second major outbreaks were 25.6% (95% CI, 0.23-0.28) vs 16.2% (95% CI, 0.13-0.19; P &lt; .001), respectively. After adjusting for country, sex, age, comorbidities, tumor stage and status, anti–COVID-19 and anticancer therapy, and COVID-19 complications, patients diagnosed in the first outbreak had an increased risk of death at 14 days (hazard ratio [HR], 1.85; 95% CI, 1.47-2.32) and 3 months (HR, 1.28; 95% CI, 1.08-1.51) compared with those diagnosed in the second outbreak. CONCLUSIONS AND RELEVANCE: The findings of this registry-based study suggest that mortality in patients with cancer diagnosed with COVID-19 has improved in Europe; this improvement may be associated with earlier diagnosis, improved management, and dynamic changes in community transmission over time.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results